본문 바로가기
KERD
논문KCI 등재

Extended-spectrum β-Lactamases: Implications for the Clinical Laboratory and Therapy

Keizo Yamaguchi|Sohei Harada|Yoshikazu Ishii
대한진단검사의학회 (Korean Society For Laboratory Medicine)|2008.12|Annals of Laboratory Medicine|제28권 제6호|pp. 401-412

2

조회

0

다운로드

6

인용

0

참고문헌

키워드

Beta-lactamase
주제분류병리학

초록

Production of extended-spectrum β-lactamase (ESBL) is one of the most important resistance mechanisms that hamper the antimicrobial treatment of infections caused by Enterobacteriaceae. ESBLs are classified into several groups according to their amino-acid sequence homology. While TEM and SHV enzymes were the most common ESBLs in the 1990s, CTX-M enzymes have spread rapidly among Enterobacteriaceae in the past decade. In addition, some epidemiological studies showed that organisms producing CTX-M enzymes had become increasingly prevalent in the community setting in certain areas in the world. Several novel enzymes with hydrolyzing activity against oxyimino-cephalosporins, albeit with additional enzymatic characteristics different from those of original TEM and SHV ESBLs (e.g., inhibitor-resistance), have been discovered and pose a problem on the definition of ESBLs. Although several methods to detect the production of ESBL are available in clinical laboratories, existence of other factors contributing resistance against β-lactams, e.g., inducible production of Amp-C β-lactamase by some species of Enterobacteriaceae, or inhibitorresistance in some ESBLs may hinder the detection of ESBLs with these methods. Carbapenems are stable against hydrolyzing activity of ESBLs and are regarded as the drug of choice for the treatment of infections caused by ESBL-producing Enterobacteriaceae. Although several other antimicrobial agents, such as fluoroquinolones and cephamycins, may have some role in the treatment of mild infections due to those organisms, clinical data that warrant the use of antimicrobial agents other than carbapenems in the treatment of serious infections due to those organisms are scarce for now. (Korean J Lab Med 2008;28:401-12)

Abstract

Production of extended-spectrum β-lactamase (ESBL) is one of the most important resistance mechanisms that hamper the antimicrobial treatment of infections caused by Enterobacteriaceae. ESBLs are classified into several groups according to their amino-acid sequence homology. While TEM and SHV enzymes were the most common ESBLs in the 1990s, CTX-M enzymes have spread rapidly among Enterobacteriaceae in the past decade. In addition, some epidemiological studies showed that organisms producing CTX-M enzymes had become increasingly prevalent in the community setting in certain areas in the world. Several novel enzymes with hydrolyzing activity against oxyimino-cephalosporins, albeit with additional enzymatic characteristics different from those of original TEM and SHV ESBLs (e.g., inhibitor-resistance), have been discovered and pose a problem on the definition of ESBLs. Although several methods to detect the production of ESBL are available in clinical laboratories, existence of other factors contributing resistance against β-lactams, e.g., inducible production of Amp-C β-lactamase by some species of Enterobacteriaceae, or inhibitorresistance in some ESBLs may hinder the detection of ESBLs with these methods. Carbapenems are stable against hydrolyzing activity of ESBLs and are regarded as the drug of choice for the treatment of infections caused by ESBL-producing Enterobacteriaceae. Although several other antimicrobial agents, such as fluoroquinolones and cephamycins, may have some role in the treatment of mild infections due to those organisms, clinical data that warrant the use of antimicrobial agents other than carbapenems in the treatment of serious infections due to those organisms are scarce for now. (Korean J Lab Med 2008;28:401-12)

참고문헌 (84)

  1. Livermore DM., "β-Lactamases in laboratory and clinical resistance", Clin Microbiol Rev, 8, pp.577~584 (1995)
  2. Datta N, "Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae", Nature, 208, pp.239~241 (1965)
  3. Knothe H, "Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens", Infection, 11(1), pp.315~317 (1983)
  4. Jacoby G, "Lahey clinic page on amino acid sequence for TEM, SHV and OXA extended-spectrum and inhibitor resistant β-Lactamases. http:", Studies, pp.(Updated on Sep 24, 2008)[DOI]
  5. Bernard H, "A novel plasmid-mediated extended-spectrum β-lactamase not derived from TEM- or SHV-type enzymes", J Antimicrob Chemother, 29, pp.590~592 (1992)
  6. Canton R, "The CTX-M β-lactamase pandemic", Curr Opin Microbiol, 9, pp.466~475 (2006)
  7. Bonnet R., "Growing group of extended-spectrum β-lactamases: the CTX-M enzymes", Antimicrob Agents Chemother, 48, pp.1~14 (2004)
  8. Rossolini GM, "The spread of CTXM-type extended-spectrum β-lactamases", Clin Microbiol Infect, 14(S), pp.S33~S41 (2008)
  9. Ambler RP., "The structure of β-lactamases", Philos Trans R Soc Lond B Biol Sci, 289, pp.321~331 (1980)
  10. Bush K, "A functional classification scheme for β-lactamases and its correlation with molecular structure", Antimicrob Agents Chemother, 39, pp.1211~1233 (1995)
  11. Livermore DM, "Defining an extended-spectrum β-lactamase", Clin Microbiol Infect, 14(S), pp.S3~S10 (2008)
  12. Livermore DM., "Clinical significance of β-lactamase induction and stable derepression in gram-negative rods", Eur J Clin Microbiol, 6, pp.439~445 (1987)
  13. Philippon A, "Plasmid-determined AmpC-type β-lactamases", Antimicrob Agents Chemother, 46, pp.1~11 (2002)
  14. Mammeri H, "Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate", Antimicrob Agents Chemother, 48, pp.716~720 (2004)
  15. Barnaud G, "Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate", Antimicrob Agents Chemother, 48, pp.1040~1042 (2004)
  16. Mammeri H, "AmpC β-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins", Antimicrob Agents Chemother, 48, pp.4050~4053 (2004)
  17. Wachino J, "Horizontal transfer of blaCMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19", Antimicrob Agents Chemother, 50, pp.534~541 (2006)
  18. Kim JY, "Structural basis for the extended substrate spectrum of CMY-10, a plasmidencoded class C β-lactamase", Mol Microbiol, 60, pp.907~916 (2006)
  19. Queenan AM, "Carbapenemases: the versatile β-lactamases", Clin Microbiol Rev, 20, pp.440~458 (2007)
  20. Poirel L, "Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β- lactamase, and the class 1 integron In52 from Klebsiella pneumoniae", Antimicrob Agents Chemother, 44, pp.622~632 (2000)
  21. Poirel L, "GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem", Antimicrob Agents Chemother, 45, pp.2598~2603 (2001)
  22. Wachino J, "Molecular characterization of a cephamycin-hydrolyzing and inhibitor- resistant class A β-lactamase, GES-4, possessing a single G170S substitution in the omega-loop", Antimicrob Agents Chemother, 48, pp.2905~2910 (2004)
  23. Matthew M, "Types of β-lactamase determined by plasmids in gram-negative bacteria", J Bacteriol, 138, pp.657~662 (1979)
  24. Babini GS, "Are SHV β-lactamases universal in Klebsiella pneumoniae?", Antimicrob Agents Chemother, 44, pp.2230~ (2000)
  25. Kliebe C, "Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins", Antimicrob Agents Chemother, 28, pp.302~307 (1985)
  26. Heritage J, "Evolution and spread of SHV extended-spectrum β-lactamases in gram-negative bacteria", J Antimicrob Chemother, 44, pp.309~318 (1999)
  27. Huletsky A, "Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type β- lactamases probed by site-directed mutagenesis and three-dimensional modeling", J Biol Chem, 268, pp.3690~3697 (1993)
  28. Ford PJ, "Evolutionary mapping of the SHV β-lactamase and evidence for two separate IS26-dependent blaSHV mobilization events from the Klebsiella pneumoniae chromosome", J Antimicrob Chemother, 54, pp.59~75 (2004)
  29. Miriagou V, "IS26- associated In4-type integrons forming multiresistance loci in enterobacterial plasmids", Antimicrob Agents Chemother, 49, pp.3541~3543 (2005)
  30. Preston KE, "The SHV-5 extended-spectrum β-lactamase gene of pACM1 is located on the remnant of a compound transposon", Plasmid, 51, pp.48~53 (2004)
  31. Bradford PA, "Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat", Clin Microbiol Rev, 14, pp.933~951 (2001)
  32. Sirot D, "Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase", J Antimicrob Chemother, 20, pp.323~334 (1987)
  33. Sougakoff W, "The TEM-3 β-lactamase, which hydrolyzes broad-spectrum cephalosporins, is derived from the TEM-2 penicillinase by two amino acid substitutions", FEMS Microbiol Lett, 56, pp.343~348 (1988)
  34. Canton R, "IRT and CMT β-lactamases and inhibitor resistance", Clin Microbiol Infect, 14(S), pp.S53~S62 (2008)
  35. Robin F, "CMT-type β-lactamase TEM-125, an emerging problem for extended-spectrum β-lactamase detection", Antimicrob Agents Chemother, 50, pp.2403~2408 (2006)
  36. Bauernfeind A, "A new plasmidic cefotaximase in a clinical isolate of Escherichia coli", Infection, 18, pp.294~298 (1990)
  37. Barthelemy M, "Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum β-lactamase MEN-1 and chromosomally encoded enzymes of Klebsiella oxytoca", Biochim Biophys Acta, 1122, pp.15~22 (1992)
  38. Bauernfeind A, "A new plasmidic cefotaximase from patients infected with Salmonella typhimurium", Infection, 20, pp.158~163 (1992)
  39. Ishii Y, "Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A β-lactamase isolated from Escherichia coli", Antimicrob Agents Chemother, 39, pp.2269~2275 (1995)
  40. Bauernfeind A, "Sequences of β-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other β-lactamases", Antimicrob Agents Chemother, 40, pp.509~513 (1996)
  41. Humeniuk C, "β-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types", Antimicrob Agents Chemother, 46, pp.3045~3049 (2002)
  42. Poirel L, "Chromosome-encoded Ambler class A β-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases", Antimicrob Agents Chemother, 46, pp.4038~4040 (2002)
  43. Rodriguez MM, "Chromosome-encoded CTX-M-3 from Kluyvera ascorbata: a possible origin of plasmid-borne CTX-M-1-derived cefotaximases", Antimicrob Agents Chemother, 48, pp.4895~4907 (2004)
  44. Olson AB, "Identification of a progenitor of the CTX-M-9 group of extended-spectrum β-lactamases from Kluyvera georgiana isolated in Guyana", Antimicrob Agents Chemother, 49, pp.2112~2115 (2005)
  45. Lartigue MF, "In vitro analysis of ISEcp1B-mediated mobilization of naturally occurring β-lactamase gene blaCTX-M of Kluyvera ascorbata", Antimicrob Agents Chemother, 50, pp.1282~1286 (2006)
  46. Poirel L, "Insertion sequence ISEcp1B is involved in expression and mobilization of a blaCTX-M β-lactamase gene", Antimicrob Agents Chemother, 47, pp.2938~2945 (2003)
  47. Rodriguez-Martinez JM, "Common region CR1 for expression of antibiotic resistance genes", Antimicrob Agents Chemother, 50, pp.2544~2546 (2006)
  48. Oliver A, "CTX-M-10 linked to a phage-related element is widely disseminated among Enterobacteriaceae in a Spanish hospital", Antimicrob Agents Chemother, 49, pp.1567~1571 (2005)
  49. Yu WL, "Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae", Emerg Infect Dis, 8, pp.522~524 (2002)
  50. Chen Y, "Atomic resolution structures of CTX-M β-lactamases: extended spectrum activities from increased mobility and decreased stability", J Mol Biol, 348, pp.349~362 (2005)
  51. Ibuka AS, "Crystal structure of extended-spectrum β-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion", Biochemistry, 42, pp.10634~10643 (2003)
  52. Kimura S, "Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis", Antimicrob Agents Chemother, 48, pp.1454~1460 (2004)
  53. Ishii Y, "Biochemical characterisation of the CTX-M-14 β-lactamase", Int J Antimicrob Agents, 29, pp.159~164 (2007)
  54. Pitout JD, "Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community", J Antimicrob Chemother, 56, pp.52~59 (2005)
  55. Walther-Rasmussen J, "OXA-type carbapenemases", J Antimicrob Chemother, 57, pp.373~383 (2006)
  56. Naas T, "Minor extended-spectrum β-lactamases", Clin Microbiol Infect, 14(S1), pp.S42~S52 (2008)
  57. Paterson DL, "Extended-spectrum β-lactamases: a clinical update", Clin Microbiol Rev, 18, pp.657~686 (2005)
  58. Paterson DL, "Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory", J Clin Microbiol, 39, pp.2206~2212 (2001)
  59. "Health Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings"[URL]
  60. Kahlmeter G, "Breakpoints for intravenously used cephalosporins in Enterobacteriaceae -EUCAST and CLSI breakpoints", Clin Microbiol Infect, 14(S), pp.S169~S174 (2008)
  61. Weber DA, "Diverse potential of β-lactamase inhibitors to induce class I enzymes", Antimicrob Agents Chemother, 34, pp.156~158 (1990)
  62. Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility tasting; 18th informational supplement. M100-S18" (2008), Clinical and Laboratory Standards Institute
  63. Brenwald NP, "An outbreak of a CTX-M-type β-lactamase-producing Klebsiella pneumoniae: the importance of using cefpodoxime to detect extended- spectrum β-lactamases", J Antimicrob Chemother, 51, pp.195~196 (2003)
  64. Jarlier V, "Extended broadspectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns", Rev Infect Dis, 10, pp.867~878 (1988)
  65. Thomson KS, "Detection of extended-spectrum β- lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests", Antimicrob Agents Chemother, 36, pp.1877~1882 (1992)
  66. Tzelepi E, "Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes", J Clin Micro- biol, 38, pp.542~546 (2000)
  67. Sturenburg E, "Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum β-lactamases in an Enterobacteriaceae strain collection", J Antimicrob Chemother, 54, pp.134~138 (2004)
  68. Leverstein-van Hall MA, "Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum β-lactamases in multiresistant Escherichia coli and Klebsiella spp", J Clin Microbiol, 40, pp.3703~3711 (2002)
  69. Wiegand I, "Detection of extended-spectrum β-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures", J Clin Microbiol, 45, pp.1167~1174 (2007)
  70. Thomson KS, "Comparison of Phoenix and VITEK 2 extended-spectrum-β- lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized beta-lactamases", J Clin Microbiol, 45, pp.2380~2384 (2007)
  71. Sanguinetti M, "Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum β-lactamase detection method", J Clin Microbiol, 41, pp.1463~1468 (2003)
  72. Spanu T, "Evaluation of the new VITEK 2 extended-spectrum β- lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates", J Clin Microbiol, 44, pp.3257~3262 (2006)
  73. Sturenburg E, "Comparison of BD Phoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum β-lactamase detection in Escherichia coli and Klebsiella species clinical isolates", Diagn Microbiol Infect Dis, 45, pp.29~34 (2003)
  74. Jeong SH, "Boronic acid disk tests for identification of extended-spectrum β-lactamase production in clinical isolates of Enterobacteriaceae producing chromosomal AmpC β-lactamases", Int J Antimicrob Agents, 31, pp.467~471 (2008)
  75. Song W, "Detection of extended-spectrum β-lactamases by using boronic acid as an AmpC β-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli", J Clin Microbiol, 45, pp.1180~1184 (2007)
  76. Pitout JD, "Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern", Lancet Infect Dis, 8, pp.159~166 (2008)
  77. Paterson DL, "Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases", Clin Infect Dis, 39, pp.31~37 (2004)
  78. Lautenbach E, "Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae", Clin Infect Dis, 33, pp.1288~1294 (2001)
  79. Paterson DL, "Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia", Clin Infect Dis, 30, pp.473~478 (2000)
  80. Thomson KS, "Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase- producing Enterobacteriaceae", Antimicrob Agents Chemother, 45, pp.3548~3554 (2001)
  81. Bedenic B, "Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum β-lactamases", Clin Microbiol Infect, 7, pp.626~635 (2001)
  82. Bin C, "Outcome of cephalosporin treatment of bacteremia due to CTXM- type extended-spectrum β-lactamase-producing Escherichia coli", Diagn Microbiol Infect Dis, 56, pp.351~357 (2006)
  83. Endimiani A, "Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin", Clin Infect Dis, 38, pp.243~251 (2004)
  84. Kang CI, "Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy", Antimicrob Agents Chemother, 48, pp.4574~4581 (2004)

관련 논문AI추천

Rapid Detection of Extended Spectrum β-Lactamase (ESBL) for Enterobacteriaceae by use of a Multiplex PCR-based Method김성한, 김준영, 박미선, 이복권, 이지나, 이호근, 이환종, 전세미대한감염학회 · Infection and Chemotherapy2009 · 제41권 제3호Prevalence of the Extended-Spectrum β-Lactamase and qnr Genes in Clinical Isolates of Escherichia coli어영, 강현경, 김재석, 김주원, 박용정, 배일권, 이경원, 정석훈대한진단검사의학회 · Annals of Laboratory Medicine2009 · 제29권 제3호Molecular Characteristics of Extended Spectrum β-Lactamases in Escherichia coli and Klebsiella pneumoniae and the Prevalence of qnr in Extended Spectrum β-Lactamase Isolates in a Tertiary Care Hospital in Korea김명희, 박경선, 서진태, 이희주연세대학교의과대학 · Yonsei Medical Journal2010 · 제51권 제5호Frequency of Extended-spectrum b-lactamase (ESBL) and AmpC b-lactamase Genes in Escherichia coli and Klebsiella pneumoniae over a Three-year Period in a University Hospital in Korea박건, 김영숙, 문대수, 박영진, 배일권, 신종희, 이학민, 장숙진대한진단검사의학회 · Annals of Laboratory Medicine2010 · 제30권 제6호Extended-spectrum β-lactamases (ESBL) 성질을 가진 세균에 의한 요로감염이길호대한요로생식기감염학회 · Urogenital Tract Infection2011 · 제6권 제1호Ambler Class A Extended-Spectrum β-Lactamase 생성 Escherichia coli와 Klebsiella pneumoniae의국내분리현황어영, 강정옥, 강지혜, 권수봉, 김의종, 박연준, 배일권, 신종희, 안지영, 용동은, 우건조, 이경원, 이위교, 이종욱, 정석훈, 홍성근대한임상미생물학회 · Annals of Clinical Microbiology2005 · 제8권 제1호

이 간행물의 다른 논문 (12건)

다발골수종 환자의 염색체 이상과 예후관련 검사항목과의 연관성-단일 기관 연구장윤환, 홍영준, 홍석일, 이진경, 이지원pp. 413-418폐색전증 진단을 위한 D-dimer 검사의 유용성: 단일기관연구윤순규, 최태윤, 서영익, 신정원, 김양기, 박노진, 어수택pp. 419-424갑상샘암 환자에서 방사성 요오드(I¹³¹) 치료 후 발생한 혈액종양 4예이진경, 이하나, 강혜진, 천기정, 홍영준, 홍석일, 장윤환, 류백렬, 임미정, 나임일pp. 425-429Human Telomerase Reverse Transcriptase (hTERT): Cisplatin-내성 암의 치료를 위한 목적 단백질윤도영, 이희구, 박주원, 김광동, 박육필, 김종완, 강성호pp. 430-437Salivette으로 채취한 타액의 아밀라제 측정박정란, 송경은, 우정민, 김미혜, 이승재pp. 438-443
원문 보기